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Background: KRAS mutations are frequently found in colorectal cancer (CRC) indicating the importance of its
genotyping in the study of the molecular mechanisms behind this disease. Although major advances have occurred
over the past decade, there are still important gaps in our understanding of CRC carcinogenesis, particularly whether
sex-linked factors play any role.
Methods: The profile of KRAS mutations in the Brazilian population was analyzed by conducting direct sequencing of
KRAS codons 12 and 13 belonging to 8,234 metastatic CRC patient samples. DNA was extracted from paraffin-embedded
tissue, exon 1 was amplified by PCR and submitted to direct sequencing. The data obtained was analysed comparing
different geographical regions, gender and age.
Results: The median age was 59 years and the overall percentage of wild-type and mutated KRAS was 62.8% and
31.9%, respectively. Interestingly, different percentages of mutated KRAS patients were observed between male and
female patients (32.5% versus 34.8%, respectively; p = 0.03). KRAS Gly12Asp mutation was the most prevalent for both
genders and for most regions, with the exception of the North where Gly12Val was the most frequent mutation found.
Conclusions: To the best of our knowledge this is one of the largest cohorts of KRAS genotyping in CRC patients and
the largest to indicate a higher incidence of KRAS mutation in females compared to males in Brazil. Nevertheless,
further research is required to better address the impact of gender differences in colorectal cancer.
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Personalised medicine is an evolving field that seeks to
target cancer therapies based on unique genetic charac-
teristics of the tumour and/or the patient [1]. One of the
most significant advances towards personalised care in
the field of oncology was the establishment of KRAS
gene mutation as a validated biomarker predicting efficacy
in epidermal growth factor receptor (EGFR) targeted
therapies – such as cetuximab and panitumumab - in the
treatment of metastatic colorectal cancer (mCRC) [2,3].
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article, unless otherwise stated.new cancer cases and of death by cancer in the United
States with an estimate of 73,420 new cases for males and
70,040 new cases for females in 2012. In Brazil, data pub-
lished by the Brazilian National Cancer Institute predicted
the number of new cases for 2012 of 14,180 for males and
15,960 for females with a frequency variation depending on
the country’s region (data available online at http://portal.
saude.sp.gov.br/resources/ses/perfil/gestor/homepage/
estimativas-de-incidencia-de-cancer-2012/estimativas_
incidencia_cancer_2012.pdf ). The Southeast region
shows the highest incidence of CRC, being the second
most frequent cause of cancer for both men (22/100,000)
and women (23/100,000). The differences observed in the
incidence of CRC according to different Brazilian regions
could relate to the idea that differences in patients originstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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candidate cancer genes such as KRAS [5].
In order to understand KRAS function it is important
to address how Ras proteins are activated. The Ras pro-
tein family belongs to a group of small GTPases, which
are able to cycle between an inactive (GDP-bound form)
and an active state (GTP-bound form) leading to the ac-
tivation of several effector kinases. These proteins are in-
volved in cell proliferation, differentiation and survival,
hence its importance in cancer research [6]. Mutations
in RAS proto-oncogenes (comprising H-, N- and K-RAS)
are among the most common in malignant tumours and
although RAS isoforms are very similar, KRAS is more
frequently found mutated in cancers occurring in 22% of
all tumours analysed compared to 8% for NRAS and 3%
for HRAS [7]. In mCRC, mutation in KRAS gene result
in continuous activation of intracellular EGFR pathway
regardless the pharmacological blocking of the receptor
[8]. Thus, proliferation, invasion, survival and metastasis
of the tumour are maintained. Clinically, patients with
KRAS wild-type tumours are more likely to respond to
anti-EGFR therapy whereas those with mutant KRAS
show lack of benefit [9-14]. Therefore, anti-EGFR mono-
clonal antibodies are only indicated in patients with
KRAS wild-type tumours [15].
Since June 2008, a Merck Serono Oncology sponsored
program began to reimburse for KRAS mutation ana-
lyses in mCRC patients in Brazil. Almost all KRAS muta-
tions tests were performed in a single molecular biology
facility. A total of 8,234 patients had their primary
tumour and/or metastasis analysed through the pro-
gram. Here, some epidemiological characteristics of the
KRAS mutations are described.
Methods
Ethics statement
The local ethical committee (Comitê de Ética em Pesquisas-
CEP from Hospital Pró-Cardíaco, Esho Empresa de Servi-
ços Hospitalares) was consulted and approved the analysis
and publication of the epidemiological data without pa-
tient’s individual informed consent.
Merck Serono Oncology KRAS Program in Brazil
Launched in June 2008, the Merck Serono Oncology KRAS
Program invited physicians to request KRAS tests for any
patient diagnosed with mCRC. Initially, the program was
based in written formulary requests and telephone/fax
contacts to provide authorizations for tests to be per-
formed. In October 2009, the program was upgraded to
internet-based process. All physicians had to accept the
terms of the program, which comprehended no obligation
in any kind of prescription and clarification to the patient
that a pharmaceutical industry was covering the costs of
the tests, having no contact with the identity of thepatients or further individual results. After authorization
was granted, the biological material (paraffin blocks and
slides) was sent to the laboratory facility using Brazilian
mail express services (SEDEX). The results were confiden-
tial and sent directly from the laboratory to the physician
without report to Merck Serono.
DNA extraction
The tissue slide corresponding to the paraffin-embedded
tumour block was analysed by a trained pathologist. The
tumour area was marked and a fragment was digged out
from the tissue block using proper stylet. The DNA ex-
traction was performed using the commercial kit Magne-
Sil™ (Promega Corporation, Madison, Wisconsin, USA)
following manufacturer instructions described elsewhere.
Polymerase chain reaction (PCR)
Extracted DNA was analysed with semi-nested PCR.
The primers utilized were: KRASF1 e KRASR. The first
stage reactions were accomplished with 5 μl of DNA,
2 μl MgCl (50 mM), 5 μl Promega 10× PCR Buffer, 2 μl
KRASF1 primer (5′-GTGTGACATGTTCTAATATAGT
CA-3′) (50 pmol/μl), 2 μl KRASR primer (5′-GAATGG
TCCTGCACCAGTAA-3′) (50 pmol/μl), 5 μl sNTPS
(2,5 mM), 28,5 μl distilled water, 0,5 μl Taq Platinum
DNA Pol (Invitrogen) in total volume of 50 μl, following
a cycle program of 94°C for 1 min, 40 cycles of 95°C
during 20 seconds, 60°C during 30 seconds and 72°C for
1 min and 30 seconds and final extension of 20 min in
72°C. For the semi-nested stage, the products from first
stage PCR were diluted in 1:100 ratio in distilled water
and 5 μl were added to a mixture containing 5 μl of
DNA, 2 μl MgCl (50 mM), 5 μl Promega 10 × PCR Buf-
fer, 2 μl KRASF primer (50pmol/μl), 2 μl KRASF2
primer 5′-TCATTATTTTTATTATAAGGCCTGCTG-3′
(50 pmol/μl), 5 μl sNTPS (2,5 mM), 28,5 μl distilled
water, 0,5 μl Taq Platinum DNA Pol (Invitrogen) in total
volume of 50 μl, in cycle conditions of 94°C during
1 min, 40 cycles in 95°C for 20 seconds, 58°C for 30 sec-
onds and 72°C for 1 min and 30 seconds. All reactions
were performed using MyCycler™ Thermal Cycler (BioRad
Laboratories, Inc; Hercules, CA, USA) equipment.
The PCR products were analysed in a 2% agarose gel
and visualized under ultraviolet light. The samples were
considered positive when the band correspondent to 185
base pairs was seen. After agarose gel electrophoresis,
40 μl of PCR substrate was purified using commercial kit
GFX™ PCR DNA and Gel Purification Kit (GE Healthcare,
Piscataway, NJ, USA) following manufacture’s instructions.
DNA sequencing
The amount of 2 μl of substrate was used in sequencing
reactions using commercial kit BigDye Terminator v.3.1
Cycle Sequencing Kit (Applied Biosystems) according to
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(5′-GAATGGTCCTGCACCAGTAA-3′).
The sequences were analysed using ABI PRISM® 3100
GeneticAnalyzer/HITACHI (Applied Biosystems) and
the presence of mutations were performed using the
Mutation Surveyor (Softgenetics) software.
Statistical analysis
Parameters evaluated were frequency of mutations, fre-
quency of mutations per codons (12 or 13), types of mu-
tations, gender, age, and geographic region distributions.
Cross tabulation of interests combining some of the
mentioned parameters were analysed whenever consid-
ered of interest.
Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS software, version 13.0
for Windows, Chicago, IL, USA). The level of signifi-
cance for p value was established as below 5%.
Continuous variables were presented using mean
values and standard deviation. The categorical variables
were presented as absolute frequency and percentages.
Further associations between variables were verified
through Pearson’s chi-square test.
Results
Total frequency of wild-type versus mutant KRAS
A total of 8,234 samples were pooled for analysis. There
were 437 tests without a conclusive KRAS diagnostic.
This occurred mostly due to inadequate samples that
prevented DNA amplification related to fixation dur-
ation, type of formalin previously used and/or insuffi-
cient tumour availability. Whenever this occurred, up to
four attempts of DNA extraction and amplification were
performed before the physician requested more samples
for analysis. Figure 1 displays the total frequencies ofFigure 1 Overall percentage of mutant versus wild-type KRAS cases. A t
an inconclusive KRAS diagnostic.KRAS mutations. Our results show an overall KRAS mu-
tation frequency of 31.9% (n = 8,234).
Analysis of KRAS according to regions
Brazil has a territory of continental size showing a strong
ancestral diversity: the result of interethnic crosses between
different populations: the European colonizers (mainly
Portuguese), African slaves and Amerindians [16]. For ex-
ample, the Northeast region has a history of strong African
presence due to slavery, the South was mostly settled by
European immigrants and the North by Amerindians [17].
The Brazilian population admixture has important
clinical implications [17]. Different population origins
may determine different trends in gene mutations, there-
fore we analysed samples coming from patients from the
five different regions of Brazil. The distribution of KRAS
mutations according to geographic region is shown in
Table 1. Each region showed more than 30% incidence
of KRAS mutant cases, being the Southeast the highest
and the Northeast region the lowest in incidence. The
distribution between genders of study population was
well balanced between female (48.1%) and male (51.9%).
The mean age of the population analysed was 58.8 years
(standard deviation 13.02 range 14 to 102). The mean
age for the presence of mutations was 60 years and for
its absence, 59 years.
Types of mutations and their geographical distribution
After considering the different geographical regions and
obtaining the result of mutant versus wild-type samples
per region, we performed genotyping of KRAS codons
12 and 13, which are the most commonly affected co-
dons in CRC also known to be predictors of resistance
to anti-EGFR therapies [3]. By doing this, we accessed
the frequent aminoacid changes. Although recent studiesotal of 8,234 samples were pooled for analysis and 437 tests presented




Wild-type Mutant Total n (%)
n (%) n (%) 8,234 (100)
Southeast 3,026 (65.3) 1,608 (34.7) 4,634 (56.3)
South 1,091 (68) 514 (32) 1,605 (19.5)
Northeast 558 (69.1) 250 (30.9) 808 (9.8)
Middle west 387 (66.5) 195 (33.5) 582 (7.1)
North 93 (65.5) 49 (34.5) 142 (1.7)
Missing data - - 463 (5.6)
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quently found mutated in CRC) [18], at the time we
started our study mutational analysis of KRAS codons 12
and 13 was standard for patients with mCRC.
The correlation between geographic distribution and
KRAS mutations was available for 8,208 tests (99.7% of all
performed tests). Overall, the mutation Gly12Asp (GGT >
GAT) was the highest in most regions with the exception
of the North where Gly12Val (GGT >GTT) was the most
frequent. The Middle West region showed the highest
percentage of Gly12Asp (GGT>GAT) mutations, whereas
the North showed the least. At codon 13, the most preva-
lent modification was Gly13Asp (GGC >GAC), followed
by other low frequent alterations. The percentage of muta-
tions according to each region ranged from 30.9% (North-
east) to 34.7% (Southeast). Details on the distribution and
types of mutations are described in Table 2.Distribution of different KRAS mutations according
to gender
Gender was tested as one of the factors that could be
relevant in our analysis since it is known that in different
populations, women and men are affected differently byTable 2 Incidence of KRAS mutations according to region
Mutation
Middle west n (%) Northeast n (%
195 (100) 250 (100)
Gly12Asp (GGT > GAT) 79 (40.5) 99 (39.6)
Gly12Val (GGT > GTT) 48 (24.6) 53 (21.2)
Gly12Cys (GGT > TGT) 14 (7.2) 21 (8.4)
Gly12Ala (GGT > GCT) 12 (6.2) 14 (5.6)
Gly12Ser (GGT > AGT) 12 (6.2) 24 (9.6)
Gly12Arg (GGT > CGT) 6 (3.1) 5 (2)
Gly13Asp (GGC > GAC) 24 (2.3) 34 (13.6)
Gly13Cys (GGC > TGC) 0 0
Gly13Ser (GGC > AGC) 0 0
Gly13Val (GGC > GTT) 0 0
Gly13Arg (GGC > CGC) 0 0
Total/region (100) 33.5% 30.9%CRC, where men are at higher risk [19]. Table 3 shows
that mutations in codon 12 were much more prevalent
than in codon 13 (83% and 17%, respectively) and the
distribution of mutations according to both codons did
not differ by gender (p = 0.34). Overall, the most frequent
point mutation in codon 12 was Gly12Asp (GGT >GAT),
being found in 36.4% of all mutant samples followed by
Gly12Val (GGT >GTT) (24.3%) and Gly12Cys (GGT >
TGT) (7.9%). In codon 13, Gly13Asp (GGC >GAC) was
the most common mutation (16.1%). The KRAS mutation
profile according to gender correlated well with the overall
KRAS mutant type, being Gly12Asp (GGT>GAT) the
most frequent mutation in each gender. A detailed de-
scription of the mutations identified is shown in Table 3.Association between gender, KRAS mutation and age
Our results have shown that the Gly12Asp mutation was
the most prevalent for males and females, thus we further
investigated this by analysing the overall incidence of mu-
tant cases according to gender. The most striking result
observed in our database was the fact that KRAS muta-
tions affected more women compared to men (34.8% vs.
32.5%, respectively, p = 0.03) as can be seen in Table 4.
This result led us to stratify the mutant cases also ac-
cording to age, since sex hormones play an important
role during a life cycle especially during female repro-
ductive events. The age groups were ≤40, 40–50, 50–60,
60–70 and ≥70.
Figure 2 examines the mutational status differences
observed according to age and sex. Corroborating results
shown in Table 4, the percentages of mutations in females
are higher for the ages ≤40 (p = 0.27), 40–50 (p = 0.02)
and 50–60 (p = 0.02) when compared to males. In
contrast, ages 60–70 (p = 0.47) and ≥70 (p = 0.73) showed
a different result, where more males have mutations.) North n (%) Southeast n (%) South n (%)
49 (100) 1,610 (100) 515 (100)
15 (30.6) 587 (36.5) 174 (33.8)
16 (32.7) 397 (24.7) 124 (24.1)
6 (12.2) 114 (7.1) 50 (9.7)
1 (2) 90 (5.6) 32 (62)
4 (8.2) 125 (7.8) 29 (5.6)
2 (4.1) 16 (1) 5 (1)
4 (8.2) 264 (16.4) 96 (18.6)
0 11 (0.7) 2 (0.4)
1 (2) 3 (0.2) 1 (0.2)
0 1 (0.1) 1 (0.2)
0 2 (0.1) 1 (0.2)
34.5% 34.7% 32.0%
Table 3 Frequency of KRAS mutations and types of








1,305 (100) 1,318 (100) 2,623 (100)
Codon 12 1,082 (83) 1,093 (83) 2,175 (83)
Gly12Asp (GGT > GAT) 457 (35) 498 (37.8) 955 (36.4)
Gly12Val (GGT > GTT) 312 (23.9) 325 (24.7) 637 (24.3)
Gly12Ser (GGT > AGT) 102 (7.8) 92 (7) 194 (7.4)
Gly12Ala (GGT > GCT) 78 (6) 71 (5.4) 149 (57)
Gly12Cys (GGT > TGT) 112 (8.6) 94 (7.1) 206 (7.9)
Gly12Arg (GGT > CGT) 21 (1.6) 13 (1) 34 (1.3)
Codon 13 223 (17) 224 (17) 447 (17)
Gly13Asp (GGC > GAC) 215 (16.5) 208 (15.8) 423 (16.1)
Gly13Cys (GGC > TGC) 3 (0.2) 10 (0.8) 13 (0.5)
Gly13Ser (GGC > AGC) 3 (0.2) 3 (0.2) 6 (0.2)
Gly13Val (GGC > GTT) 1 (0.1) 1 (0.1) 2 (0.1)
Gly13Arg (GGC > CGC) 1 (0.1) 2 (0.2) 3 (0.1)
Gly12Ser (GGT > TTT)* - - 1
*Missing data.
Figure 2 Percentage of mutant KRAS cases according to sex
and age. Variables such as gender and age were analysed and the
age ranges for both sexes were: ≤40 (p = 0.27), 40–50 (p = 0.02),
50–60 (p = 0.02), 60–70 (p = 0.47) and ≥70 (p = 0.73).
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the age ranges were less dramatic (60–70 = 35.1% vs
33.6%; ≥70 = 33.9% vs 33.1%; male vs female) than the
ones observed between males and females in the
range ≤40 (30.3% vs 34.3%; p = 0.27), 40–50 (30.8% vs
37%; p = 0.02), 50–60 (31.3% vs 36.1%; p = 0.02).
Discussion
In the colorectal carcinogenesis model initially described
by Vogelstein [20], specific genetic events would be re-
lated to morphological tissue changes. Among these
genetic changes, different studies have shown that muta-
tions in the KRAS gene were found in over 30% of CRC
and advanced adenomas [21,22]. The present study is
consistent with this showing that among the 8,234 cases
analysed, a total of 2,623 (31.9%) corresponded to mu-
tant KRAS (Figure 1). From the 2,623 mutated cases,
83% were in codon 12 versus 17% in codon 13, being the
aminoacid change Gly to Asp the most common for
both codons and genders (Table 3). The prevalence of
Gly12Asp mutation over other mutations corroborates
with data from other populations around the world
[23,24]. Despite variations in the frequency of types of
mutations per region (Table 2), our results showed thatTable 4 KRAS status according to gender
Gender
KRAS wild-type n (%) KRAS mutant n (%) Total n (%)
5,174 (66.4) 2,623 (33.6) 7,797 (100)
Female 2,440 (65.2) 1,305 (34.8) 3,745 (100)
Male 2,734 (67.5) 1,318 (32.5) 4,052 (100)more than 30% of the patients in each region harboured
KRAS mutations (Table 1). Regarding prognosis, previ-
ously published data showed that Gly12Val substitutions
are more aggressive having a poorer prognosis than
those with Gly12Asp mutation, thus revealing a connec-
tion between survival and KRAS mutation type [23,25-27].
In relation to codon 13, some studies have shown that
mutations in this codon could be less aggressive than in
codon 12 and that patients with KRAS Gly13Asp mutant
tumours could benefit from anti-EGFR therapies [28,29].
In addition, recent in vitro studies have confirmed that
Gly13Asp mutations are associated with sensitivity to
anti-EGFR antibody treatments [30,31]. Unfortunately, we
were unable to provide prognosis comparisons since we
could not retrieve the follow up from many patients in
our cohort.
Gender was another variable we analysed in our co-
hort. The percentages of KRAS mutations pointed out a
female over male prevalence (Table 4, p < 0.05). Actually,
the female predominance of KRAS mutations in CRC
patients has been reported in few recent studies per-
formed in smaller cohorts from Asia. In China, a cohort
of 167 CRC patients were tested for mutations on KRAS
codons 12 and 13 and their results detected a higher rate
of KRAS mutations in female compared to male patients
[32] and this finding did not significantly correlate with
the patient age, tumour site, differentiation grades and
histological types. Differently to our data, their results
referred to Gly13Asp as the most frequently mutation
identified [32]. In another Chinese study, Shen et al. [33]
observed that in a cohort of 118 CRC patients, there was
also a higher incidence of KRAS mutations in female pa-
tients compared to male patients (44.7% vs 28.2%, p =
0.037). In Japan, researchers suggested that gender and
age were independent risk factors for KRAS mutations
[34]. Another publication did not show correlation be-
tween gender and KRAS mutational status [35], and one
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differences in populations studied. Nevertheless, it is im-
portant to address that the greatest prevalence of KRAS
mutation in women has been previously observed in
other cancer types such as in patients with lung adeno-
carcinoma, leading to the hypothesis of possible hormo-
nal influence [36].
Clinical evidence suggests potential sex-related differ-
ences in the development and prognosis of CRC, which
could be associated with sex hormones. Estrogens and
androgens regulate growth, differentiation and function-
ing of different tissues, including the gastrointestinal
tract. Estrogen is an important mitogen capable of send-
ing its signal to the nucleus via interaction with estrogen
receptors (ER) on target cells. The two distinct estrogen
receptors (ERα and ERβ) tend to respond differently to
estrogen. The high proliferative activity triggered by es-
trogen is related to its connection to the ERα, which can
help tumoral development by increasing the probability
of genetic mutations [37]. In contrast, the ERβ forms
heterodimers with the ERα blocking their proliferative
activity by suppression of oncogenic transcription factors
(e.g. c-myc, cyclin D1 e cyclin A) and by stimulating the
expression of tumour suppressing genes (e.g. p21 e p27)
[38]. The expression of the ERβ is significantly reduced
in adenomatous tissues and in colon tumours, when
compared to normal mucosa in both genders, however
with a slight reduction in females (p < 0.002) [39-41].
Nevertheless, there are no observed changes in the ex-
pression of ERα between the different tissues. Also in
pre-cancerous lesions with a high risk of CRC develop-
ment, a decrease in ERβ expression could indicate a pro-
moting factor for the development of cancer [42]. In
hereditary nonpolyposis colon cancer syndrome (HNPCC)
characterised by a dominant susceptibility acquired in the
early appearance of symptoms of CRC, the average age for
CRC diagnosis is earlier in males than females (38.8 vs
47.2; p < 0.05) [19], indicating that female sexual hor-
mones could be acting as protective factors. This estrogen
protectiveness was also the conclusion after guinea pigs
that were treated with PhiP (2-Amino-1-methyl-6-pheny-
limidazo [4,5-b] pyridine), an inducing agent for colon
cancer, resulted in the average number of aberrant crypt
foci higher in males than in females (p < 0.001) [43]. In re-
gard to hormone replacement therapy, meta-analysis stud-
ies have confirmed the reverse association with the risk of
developing CRC [44-47].
The role that male sexual hormones play in the risk
for CRC is still unclear. There is evidence of reverse as-
sociation between the serum level of the dehydroepian-
drosterone sulfate and the risk of CRC [48]. The
increase of CAG trinucleotide repetitions in the coding
sequence of the androgen receptor seems to be related
to the lowest trancriptional activation of this receptorresulting in a lower androgenic action on the tissues, in-
creasing the risk of developing colon cancer [49]. Gillessen
et al. [50] confirmed in a large retrospective evaluation of
107,859 patients with prostate cancer that patients treated
with Gonadotrophin-releasing hormone (GnRH) antagon-
ist or orchiectomy presented an increase of 30-40% risk of
developing CRC when compared to the subgroup that
were not submitted to androgenic deprival.
Kato et al. [51,52] showed that the estrogen receptor is
involved in the KRAS mediated transcription and its im-
plication in the senescence escape. Furthermore, an as-
sociation between KRAS and estrogen receptor was also
observed when mutant KRAS (Gly12Val) was overex-
pressed in NIH-3 T3 cells, which resulted in increased
levels of the endogenous estrogen receptor. In addition,
the RAS signal intensified the estrogen receptor activity
as a transcription factor leading to cell transformation
[53]. In a pre-clinical study it was shown that RAS onco-
genes might remain latent in the mammary gland of
guinea pigs until estrogen exposure. This suggests that
normal proliferative processes, such as the ones induced
by estrogen in the development of the mammary gland,
could be necessary to lead cells with the latent RAS on-
cogenes to neoplastic development [54]. Collectively,
these findings could indicate an association between mu-
tant KRAS and sexual hormones.
Our observations of differences in KRAS mutational
status according to sex led us to analyse also age. KRAS
was more frequently found mutated in females than
males for the ages ≤40, 40–50, and 50–60 (Figure 2).
The age range 40–60 coincides with the menopausal
period, which is associated with a drop in estrogen
levels. In contrast, ages 60–70 and ≥70 showed a differ-
ent result, where males had more mutations than fe-
males (p > 0.05). Although the p value was higher for the
ages 60–70 and ≥70, this result could indicate an age-
linked difference associated with several causes including
men andropause. Actually, a recent study suggested that
men with lower androgenicity (resulting either from re-
duced androgen receptor activity or lower circulating de-
hydroepiandrosterone sulfate) have a higher risk for
colorectal cancer, however they did not correlate the
hormonal influence with levels of gene mutations [55].
One theory to explain our results could be that male
and female hormones may act as protective factors not
exerting pressure on the expansion of KRAS mutant
cells. However, upon menopause and andropause (events
that occur at different ages for males and females) the
decrease in hormonal levels could generate a pressure to
stimulate a molecular switch in favour of clonal selec-
tion of cells containing KRAS mutations. Nevertheless,
future studies on a large cohort corresponding to late
age ranges are necessary to further confirm these
results.
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We found that variables such as region, age and sex-
linked factors can correlate with KRAS mutational sta-
tus. This is the largest study to point out a statistically
difference in the prevalence of KRAS mutations between
genders in a cohort of brazilian mCRC patients. The
exact interaction between KRAS mutations, sexual hor-
mones and the development of CRC is still not well
defined. In the adenoma-carcinoma sequence, the prolif-
erative hormonal exposure in the presence of ERα and
the decrease of ERβ could be a factor to select KRAS
mutant clones in the adenocarcinoma histologic subtype
in females. Although estrogen could serve as a protective
hormone in CRC, it might not prevent mutations in
KRAS. Our group is currently evaluating experimentally
the reasons behind the differences observed in this
study. Hopefully, future research will be able to elucitate
the molecular links between hormones, KRAS muta-
tions, age and CRC development.
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